The history of Curasight
The lead uPAR-PET tracer candidate from this research developed into Curasight’s uTRACE® product for cancer diagnosis. At the same time Curasight pursued the idea of using uPAR as a biomarker to create a theranostic platform solution – combining detection and classification of a tumor using uTRACE with subsequent improved treatment solutions for the cancer. This led to Curasight acquiring all the international patent rights (IP) to the radionuclide uTREAT®, Curasight’s product designed to treat certain types of tumors. Curasight is currently in Phase 2 with uTRACE and in preclinical testing with uTREAT.
The history of Curasight
Curasight is built on more than a decade of research in Positron Emissions Tomography (PET) imaging in cancer at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
A scientific team led by Professor Andreas Kjaer, Curasight’s Chief Scientific Officer, developed the concept of PET imaging of urokinase-type plasminogen activator receptor (uPAR), a known marker of cancer aggressiveness, to be used for improved diagnosis, risk stratification and treatment planning/monitoring in multiple types of cancer.
The lead uPAR-PET tracer candidate from this research developed into Curasight’s uTRACE® product for cancer diagnosis. At the same time Curasight pursued the idea of using uPAR as a biomarker to create a theranostic platform solution – combining detection and classification of a tumor using uTRACE with subsequent improved treatment solutions for the cancer. This led to Curasight acquiring all the international patent rights (IP) to the radionuclide uTREAT®, Curasight’s product designed to treat certain types of tumors. Curasight is currently in Phase 2 with uTRACE and in preclinical testing with uTREAT.
